Johnson & Johnson announced the global launch of its Shockwave C2 Aero Coronary IVL Catheter designed for improved deliverability, enhanced lesion crossing and new repositioning capabilities for the… read more.
United Therapeutics Corporation announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20,… read more.
Cytokinetics, Incorporated announced the presentation of new data reinforcing the clinical profile of Myqorzo (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations… read more.
Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to… read more.
Researchers report that weight-loss surgery improves outcomes for patients with obesity and chronic kidney disease by significantly reducing the risk of kidney failure, major cardiovascular events and death…. read more.
BridgeBio Pharma, Inc. presented long-term efficacy and safety data from the ATTRibute-CM open-label extension (OLE) trial, demonstrating sustained clinical benefit of acoramidis through Month 54 in patients with… read more.
Alnylam Pharmaceuticals, Inc announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026,… read more.
A new meta-analysis of relevant clinical studies suggests that GLP 1 weight-loss drugs provide protection against heart attacks, strokes and premature death for up to 2.7 years. The… read more.
Abbott announced new late-breaking data at Heart Rhythm Society (HRS) meeting from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system… read more.
Heatwaves and coldwaves are associated with increases in major cardiovascular events that are exacerbated by air pollution.1 Concerning results on the adverse impact of climate change and pollution on… read more.
Bayer announced that the European Commission has granted approval in the European Union (EU) for Kerendia (finerenone), a selective, non-steroidal mineralocorticoid receptor antagonist (nsMRA), for the treatment of… read more.
Researchers report that GMRx2, a single daily pill combining telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg, lowers the risk of recurrent stroke by 39%. The findings from the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
